Enhanced First Trimester Screening for Trisomy 21 with Contingent Cell-Free Fetal DNA: A Comparative Performance and Cost Analysis.

[1]  N. Wald,et al.  Prenatal reflex DNA screening for Down syndrome: enhancing the screening performance of the initial first trimester test , 2016, Prenatal diagnosis.

[2]  T. Gerds,et al.  Risk of fetal loss associated with invasive testing following combined first‐trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[3]  K. Nicolaides,et al.  Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell‐free DNA test contingent on results from first‐trimester combined test , 2016, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[4]  G. Palomaki,et al.  Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures , 2015, Prenatal diagnosis.

[5]  Tianhua Huang,et al.  First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy‐associated plasma protein A, free‐β human chorionic gonadotrophin, placental growth factor, and α‐fetoprotein , 2015, Prenatal diagnosis.

[6]  T. Musci,et al.  Cell-free DNA analysis for noninvasive examination of trisomy. , 2015, The New England journal of medicine.

[7]  N. Wald,et al.  Performance of antenatal reflex DNA screening for Down’s syndrome , 2015, Journal of medical screening.

[8]  K. Nicolaides,et al.  Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: updated meta‐analysis , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[9]  F. Park,et al.  The first trimester: prediction and prevention of the great obstetrical syndromes. , 2015, Best practice & research. Clinical obstetrics & gynaecology.

[10]  T. Hallahan,et al.  Cell‐free fetal DNA screening in the USA: a cost analysis of screening strategies , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[11]  K. Nicolaides,et al.  UK NHS pilot study on cell‐free DNA testing in screening for fetal trisomies: factors affecting uptake , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[12]  F. D’Antonio,et al.  Procedure‐related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta‐analysis , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[13]  D. Wright,et al.  First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testing , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[14]  A. Siddiqui,et al.  Single-Nucleotide Polymorphism–Based Noninvasive Prenatal Screening in a High-Risk and Low-Risk Cohort , 2014, Obstetrics and gynecology.

[15]  H. Cuckle.  Prenatal Screening Using Maternal Markers , 2014, Journal of clinical medicine.

[16]  Tianhua Huang,et al.  The price of performance: a cost and performance analysis of the implementation of cell‐free fetal DNA testing for Down syndrome in Ontario, Canada , 2014, Prenatal diagnosis.

[17]  R. Rava,et al.  Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. , 2014, Clinical chemistry.

[18]  H. Cuckle,et al.  First‐trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell‐free DNA , 2013, Prenatal diagnosis.

[19]  D. Wright,et al.  First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing , 2013, Fetal Diagnosis and Therapy.

[20]  H. Cuckle,et al.  Maternal cfDNA screening for Down syndrome – a cost sensitivity analysis , 2013, Prenatal diagnosis.

[21]  D. Wright,et al.  First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testing , 2013, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[22]  H. Cuckle,et al.  Maternal serum placental growth factor and α‐fetoprotein testing in first trimester screening for Down syndrome , 2013, Prenatal diagnosis.

[23]  G. Savva,et al.  The maternal age‐specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome) , 2010, Prenatal diagnosis.

[24]  Tianhua Huang,et al.  Prospective experience with integrated prenatal screening and first trimester combined screening for trisomy 21 in a large Canadian urban center , 2008, Prenatal diagnosis.

[25]  A. Mackinson,et al.  First and Second Trimester Antenatal Screening for Down's Syndrome: The Results of the Serum, Urine and Ultrasound Screening Study (SURUSS) , 2003, Journal of medical screening.

[26]  N J Wald,et al.  First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). , 2003, Health technology assessment.

[27]  G. B. Petersen,et al.  The selective miscarriage of Down's syndrome from 10 weeks of pregnancy , 1996, British journal of obstetrics and gynaecology.

[28]  Hook Eb.  Down syndrome rates and relaxed selection at older maternal ages. , 1983 .